Q1 2018

Alienista · 2018-07-23T23:34:00-03:00

Inogen Announces Record First Quarter 2018 Financial Results and Increases 2018 Guidance Company Release - 4/30/2018 4:05 PM ET — Q1 2018 Sales Revenue up 60.1% Over the Same Period in 2017 — GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended March 31, 2018. First Quarter 2018 Highlights Record total revenue of $79.1 million, up 50.6% over the same period in 2017 Record sales revenue of $73.6 million, up 60.1% over the same period in 2017 Rental revenue of $5.5 million, down 16.3% from the same period in 2017 GAAP net income of $10.8 million, reflecting an 81.4% increase over the same period in 2017 and a 13.6% return on revenue Adjusted EBITDA of $15.5 million, representing 42.7% growth over the same period in 2017 and a 19.6% return on revenue (see accompanying table for reconciliation of GAAP and non-GAAP measures) Total units sold were 45,400, an increase of 19,800, or 77.3%, over the same period in 2017 Press Release - Inogen, Inc.

@Alienista
em 06/08/2018 21:59

@oxe @celtiberian @wafiq @Bastter

Retorno pode não ser tudo, mas o dessa aqui chama a atenção e demanda análise concentrada.

#1 de 14

@Bastter
em 06/08/2018 22:01

#2 de 14

@rushmore
em 06/08/2018 22:03

Essa ta na lista, crescimento bem acelerado e cashflow positivo, bonito de ver

#3 de 14

@Alienista
em 06/08/2018 22:03

Apesar de ter números fortes, parece ter pouco fôlego...

#4 de 14

@MarkFord
em 06/08/2018 22:07

Redondinha.

#5 de 14

@Bastter
em 06/08/2018 22:09

#6 de 14

@MarkFord
em 06/08/2018 22:16

Essa merece um estudozinho mesmo. Os números são bons.

#7 de 14

@oxe
em 06/08/2018 22:24

"We are a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which we call the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. Our proprietary Inogen One® systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 2.8, 4.8 or 7.0 pounds with a single battery. Our Inogen One G4®, Inogen One G3® and Inogen One G2® have up to 2.6, 4.7 and 5.0 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Our Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility."

#8 de 14

@oxe
em 06/08/2018 22:27

Basicamente, ela só trabalha com isso. O produto dela é mais conveniente que os tradicionais cilindros de oxigênio, são máquinas portáteis que concentram o oxigênio da atmosfera e só precisam de recarga da bateria. Isso dá mais autonomia aos clientes.

Ela é líder mundial em concentradores de oxigênio e a única empresa dos EUA que vende esses concentradores diretamente ao consumidor.

"Based on 2016 industry data, we believe we were the leading worldwide manufacturer of portable oxygen concentrators. We believe we are the only manufacturer of portable oxygen concentrators that employs a direct-to-consumer strategy in the United States, meaning we market our products to patients, process their physician paperwork, provide clinical support as needed and bill Medicare or insurance on their behalf."

#9 de 14

@oxe
em 06/08/2018 22:34

Vale notar que o crescimento dela é sustentado no Medicare, que é um programa do governo dos EUA, uma espécie de plano de saúde público de lá. Ela fornece o produto pra PF e cobra direto do governo. Ela também prevê que o crescimento futuro será sustentado no Medicare:

"As of 2016, we estimate that there are 4.5 million patients worldwide who use oxygen therapy, including 2.5 to 3 million patients in the United States, and more than 60% of oxygen therapy patients in the United States are covered by Medicare."

Ou seja, a pipoca dela é feita com o milho do governo dos EUA. A dependência dela do Medicare parece ser maior que a das faculdades daqui do FIES.

Recomendo não se deslumbrar e controlar risco adequadamente.

#10 de 14

@Alienista
em 06/08/2018 22:52

Tá com jeitão de cavalo paraguaio.

O site deles tem estilo assim meio toscão...

https://www.inogen.com

#11 de 14

@Bastter
em 06/08/2018 23:03

#12 de 14

@oxe
em 06/08/2018 23:16

Acho que é sim, Bastter. Pelo que ela falou no relatório, os pacientes dela precisam de oxigênio pra não morrer, geralmente têm doenças crônicas e acompanhamento médico. Então acho que seria fácil de notar se não funcionasse. Além disso, tem outras empresas vendendo esse produto, só que normalmente só pra hospital. A sacada dessa aqui é vender pra PF e cobrar do governo.

Os dois riscos pra mim são:

1- depender do governo;
2- vender um produto só.

#13 de 14

@Bastter
em 06/08/2018 23:19

#14 de 14